ANO10 mutational screening in recessive ataxia: genetic findings and refinement of the clinical phenotype.
Lorenzo NanettiElisa SartoAnna CastaldoStefania MagriAlessia MongelliDavide Rossi SebastianoLaura CanafogliaMarina GrisoliChiara MalagutiFrancesca RivieriMaria Chiara D'AmicoDaniela Di BellaSilvana FranceschettiCaterina MariottiFranco TaroniPublished in: Journal of neurology (2018)
Autosomal recessive cerebellar ataxia type 3 (ARCA3) is a rare inherited disorder caused by mutations in the ANO10 gene. The disease is characterized by slowly progressive spastic ataxia variably associated with motor neuron involvement, epilepsy, and cognitive decline. We performed mutational screening in 80 patients with sporadic or autosomal recessive adult-onset ataxia. We identified 11 ANO10 gene variants in 10 patients from 8 families (10%): 4 mutations were previously described and 7 were novel. Age at onset ranged between 27 and 53 years. All patients presented ataxia, pyramidal signs and cerebellar atrophy at brain MRI. Additional signs were bradykinesia (7/10), mild vertical gaze paresis (5/10), pes cavus (4/10), and sphincteric disturbances (3/10). Six patients, with normal MMSE score, failed several neuropsychological tests rating executive functions. Three patients had giant somatosensory evoked potentials and epileptic spikes in EEG without clinical evidence of seizures. Our observational study indicates a high frequency of ARCA3 disease in sporadic patients with adult-onset cerebellar ataxia. We extended the ANO10 mutational spectrum with the identification of novel gene variants, and further defined the clinical, cognitive, and neurophysiological features in a new cohort of patients. These findings may contribute to the refinement of the complex ARCA3 phenotype and be valuable in clinical management and natural history studies.
Keyphrases
- end stage renal disease
- ejection fraction
- newly diagnosed
- cognitive decline
- high frequency
- prognostic factors
- copy number
- peritoneal dialysis
- multiple sclerosis
- dna methylation
- patient reported outcomes
- late onset
- magnetic resonance
- autism spectrum disorder
- brain injury
- transcranial magnetic stimulation
- transcription factor
- contrast enhanced
- transcranial direct current stimulation
- high density
- subarachnoid hemorrhage
- botulinum toxin
- case control